

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows, without prejudice or disclaimer. This claim listing replaces all prior claim listings.

1-66. Previously cancelled.

67. (Previously amended) An isolated peptide selected from the group consisting of SEQ ID NO.:7, SEQ ID NO.:8, SEQ ID NO.:9, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:21, SEQ ID NO.:24, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:32, SEQ ID NO.:34, SEQ ID NO.:37, SEQ ID NO.:38, SEQ ID NO.:40, SEQ ID NO.:49, SEQ ID NO.:51, SEQ ID NO.:54, SEQ ID NO.:57, SEQ ID NO.:59, SEQ ID NO.:61, SEQ ID NO.:63, SEQ ID NO.:67, SEQ ID NO.:70, SEQ ID NO.:72, SEQ ID NO.:74, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:81, SEQ ID NO.:84, and SEQ ID NO.:85, the peptide being immunogenic as determined by ELISPOT analysis of human T-cell cultures or human T cell cytotoxicity assay.

68. Previously cancelled.

69. (Previously presented) A composition comprising an isolated peptide of claim 67 and a pharmaceutically acceptable carrier.

70-72. Previously cancelled.

73. (Currently amended) ~~An~~ The isolated peptide ~~having the amino acid sequence~~ LMDMQTFKA (SEQ ID NO.:7).

74. (Previously presented) A composition comprising the isolated peptide of claim 73 in a pharmaceutically acceptable carrier.

75. (Currently amended) A composition for inducing an immune response in a host comprising the isolated peptide of claim 73 and at least one isolated peptide selected from the group consisting of SEQ ID NO.:8, SEQ ID NO.:9, SEQ ID NO.:11, SEQ ID NO.:12, SEQ ID NO.:21, SEQ ID NO.:24, ~~SEQ ID NO.:28~~, SEQ ID NO.:29, SEQ ID NO.:30, SEQ ID NO.:32, SEQ ID NO.:34, SEQ ID NO.:37, SEQ ID NO.:38, SEQ ID NO.:40, SEQ ID NO.:49, SEQ ID NO.:51, SEQ ID NO.:54, SEQ ID NO.:57, SEQ ID NO.:59, SEQ ID NO.:61, SEQ ID NO.:63, SEQ ID NO.:67, SEQ ID NO.:70, SEQ ID NO.:72, SEQ ID NO.:74, SEQ ID NO.:77, SEQ ID NO.:78, SEQ ID NO.:81, SEQ ID NO.:84, SEQ ID NO.:85, SEQ ID NO.:99, SEQ ID NO.:100, SEQ ID

NO.:101, SEQ ID NO.:102, SEQ ID NO.:103, and SEQ ID NO.:104, and a pharmaceutically acceptable carrier.

76. (Currently amended) A method for inducing an immune response against the tumor antigen BFA5 (SEQ ID NO.: 6) in a host comprising administering to the host the isolated peptide of claim 73.
77. (Currently amended) A method for inducing an immune response against the tumor antigen BFA5 (SEQ ID NO.: 6) in a host comprising administering to the host the composition of claim 74.
78. (Currently amended) A method for inducing an immune response in a host against the tumor antigen BFA5 (SEQ ID NO.: 6) comprising administering to the host the composition of claim 75.